Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Filament Health Corp N.FH

Alternate Symbol(s):  FLHLF

Filament Health Corp. is a Canada-based clinical-stage natural psychedelic drug development company. The Company’s platform of intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. The Company’s first three botanical drug candidates are standardized, purified extracts of Psilocybe cubensis fruiting bodies include: PEX010 Psilocybin - oral... see more

Recent & Breaking News (NEO:FH)

Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses

Accesswire January 10, 2023

FILAMENT HEALTH ANNOUNCES CEO YEAR END LETTER AND CHANGE TO BOARD OF DIRECTORS

Canada NewsWire December 30, 2022

Psyence and Filament Health Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care

GlobeNewswire December 15, 2022

FILAMENT HEALTH AND PSYENCE ANNOUNCE WORLDWIDE LICENSING AGREEMENT OF PSILOCYBIN CAPSULE FOR PALLIATIVE CARE

Canada NewsWire December 15, 2022

FILAMENT HEALTH ANNOUNCES NEW UNITED STATES PATENT ISSUANCES

Canada NewsWire November 30, 2022

FILAMENT HEALTH ANNOUNCES PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR ADDICTION AND MENTAL HEALTH

Canada NewsWire November 17, 2022

FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Canada NewsWire November 10, 2022

FILAMENT HEALTH TO HOST VIRTUAL INVESTOR UPDATE

Canada NewsWire October 12, 2022

Psyence Group Completes Export of Psilocybin Mushrooms to Canada

GlobeNewswire September 22, 2022

FILAMENT HEALTH AND ATMA JOURNEY CENTERS ANNOUNCE 14 SUBJECTS DOSED IN HEALTH CANADA-APPROVED PSILOCYBIN CLINICAL TRIAL

Canada NewsWire September 1, 2022

FILAMENT HEALTH APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS AND ADVISORY COUNCIL

Canada NewsWire August 24, 2022

FILAMENT HEALTH ANNOUNCES EIGHTH PATENT ISSUANCE

Canada NewsWire August 17, 2022

FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Canada NewsWire August 15, 2022

FILAMENT HEALTH ANNOUNCES PARTICIPATION IN PROJECT SOLACE

Canada NewsWire July 28, 2022

Filament Health (NEO:FH) closes $2.5M private placements

John Ballem  July 20, 2022

FILAMENT HEALTH ANNOUNCES CLOSING OF $2,500,080 PRIVATE PLACEMENT

Canada NewsWire July 13, 2022

FILAMENT HEALTH ISSUED THIRD PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE

Canada NewsWire July 12, 2022

FILAMENT HEALTH ANNOUNCES FIRST DOSING IN GROUNDBREAKING FDA-APPROVED PSILOCIN CLINICAL TRIAL

Canada NewsWire July 7, 2022

FILAMENT HEALTH ANNOUNCES SIXTH PATENT ISSUANCE

Canada NewsWire July 6, 2022

FILAMENT HEALTH ANNOUNCES PRIVATE PLACEMENT OF UNITS AND CONVERTIBLE DEBENTURE UNITS OF UP TO $2,500,000

Canada NewsWire June 30, 2022